5326-44-3

Usage

Uses

Used in Pharmaceutical Research and Organic Synthesis:
2-(acetylamino)-5-iodobenzoic acid is utilized as a reagent in pharmaceutical research and organic synthesis due to its unique chemical structure. It serves as a building block for the synthesis of complex organic molecules and contributes to the development of various pharmaceuticals.
Used in Medical Diagnostics:
In the medical diagnostics industry, 2-(acetylamino)-5-iodobenzoic acid is used for radioimaging applications. The presence of the iodine atom in its structure allows for its use in imaging techniques, enhancing the diagnostic capabilities in medical settings.
Used in the Production of Pharmaceuticals:
2-(acetylamino)-5-iodobenzoic acid is employed as a key intermediate in the production of pharmaceuticals. Its chemical properties and structure make it suitable for the synthesis of a range of medicinal compounds, contributing to the advancement of drug development.

Upstream product

• 108-24-7 acetic anhydride 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 13194-68-8 4-iodo-2-methylaniline 
• 75-36-5 acetyl chloride 
• 117324-09-1 N-(4-iodo-2-methylphenyl)acetamide 

Downstream Products

• 4449-71-2 2-methyl-3-phenyl-6-iodoquinazolin-4(3H)-one 
• 639465-97-7 2-[(E)-3-(4-Hydroxy-3-methoxy-phenyl)-acryloylamino]-5-iodo-benzoic acid 
• 40889-40-5 6-iodo-2-methylbenzo[d][1,3]oxazin-4-one 

Relevant academic research and scientific papers

Synthesis and evaluation of quinazolines as inhibitors of the bacterial cell division protein FtsZ

The bacterial cell division protein FtsZ is one of many potential targets for the development of novel antibiotics. Recently, zantrin Z3 was shown to be a cross-species inhibitor of FtsZ; however, its specific interactions with the protein are still unknown. Herein we report the synthesis of analogues that contain a more tractable core structure and an analogue with single-digit micromolar inhibition of FtsZs GTPase activity, which represents the most potent inhibitor of Escherichia coli FtsZ reported to date. In addition, the zantrin Z3 core has been converted to two potential photo-cross-linking reagents for proteomic studies that could shed light on the molecular interactions between FtsZ and molecules related to zantrin Z3.

Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase

In a quest for finding potent cytotoxic molecules, we have designed and synthesized a new scaffold by tagging quinazolinones with an acridone moiety. The new acridone-4-carboximide derivatives were evaluated for their cytotoxic potentials against the MCF7 breast cancer cell line and three colon cancer cell lines (LS174T, SW1398, and WiDr). Compound 26 showed relatively potent cytotoxic activity among the derivatives, against all the cell lines tested. Mechanistic studies for the selected derivatives 7, 8, 16, 17, 25, and 26 were conducted through in vitro EGFR tyrosine kinase inhibition studies. The results indicate that compound 26 has a better EGFR tyrosine kinase inhibitory profile. The in vitro EGFR inhibition data was correlated with the cytotoxic properties, and molecular docking studies were performed with regard to the receptor autophosphorylation sites of the protein kinase domain of the EGFR.

Isoxazolinyl derivatives of anthranilic acid as antiinflammatory agents

A number of 5-substituted-N-[4′-(substitutedphenyl) aminomethyl-5′-(substitutedphenyl)isoxazolin-2′-yl]anthranilic acids have been synthesized by the Mannich reaction of 5-substituted-N-[5′-(substitutedphenyl)isoxazolin-2′-yl]anthranilic acids, which in turn is synthesized by the reaction of 5-substituted-N-chalconylanthranilic acids. In this series, compounds 9, 11, 15 and 18 show significant protection against carrageenan induced rat's paw oedema with lower ulcerogenic liability than phenylbutazone. The most active compound of this series is N-[5′-(m-methoxy, p-hydroxyphenyl)isoxazolin-2′-yl]anthranilic acid which has shown higher antiinflammatory activity and lower ulcerogenic property than phenylbutazone.